As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

A multinational, randomized, double-blind trial comparing Entresto versus enalapril in 8,442 adult patients with symptomatic chronic heart failure (NYHA class II–IV) and systolic dysfunction ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

Novartis' Entresto is a drug approved for the treatment of heart failure with reduced ejection fraction. Entresto has the potential to gradually reverse the damage to the heart's structure and ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...